Ibogaine, a plant-derived compound given as a single, long, dream-like session, is studied for addiction, trauma-related conditions and brain injury. Human evidence for benefit is modest, from small studies without comparison groups; none addresses lifespan. The main risk is well documented: sometimes fatal heart-rhythm disturbances, magnified by other drugs and genetics. The data are too limited to establish clinical use. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting QTc (12-lead ECG) | At or below 420 ms | Arrhythmia risk |
| Heart rate | 55–80 beats per minute | Bradycardia risk |
| Blood pressure | Below 120/80 mmHg | Hypertension around dosing |
| Serum potassium | 4.0–5.0 mmol/L | Torsades risk |
| Serum magnesium | 2.0–2.5 mg/dL | QT protection |
| Serum calcium | 9.2–10.0 mg/dL | QT effect of low calcium |
| ALT and AST | ALT and AST both below 25 U/L | Liver clearance |
| eGFR | Above 90 mL/min/1.73 m² | Kidney clearance |
| CYP2D6 genotype | No established target; record phenotype | Sets exposure and dose |
| Urine drug screen | Negative for non-prescribed substances | Interactions, withdrawal seizures |
Cadence: Baseline before any dosing; continuous ECG and blood pressure from dosing through at least 24 hours; electrolytes at dosing and again 12–24 hours later; symptoms and function at 4–5 days and 1 month, then every 3–6 months